nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.08.2012

Perspectives on Systems Biology Applications in Diabetic Kidney Disease

verfasst von: Claudiu V. Komorowsky, Frank C. Brosius 3rd, Subramaniam Pennathur, Matthias Kretzler

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Diabetic kidney disease (DKD) is a microvascular complication of type 1 and 2 diabetes with a devastating impact on individuals with the disease, their families, and society as a whole. DKD is the single most frequent cause of incident chronic kidney disease cases and accounts for over 40 % of the population with end-stage renal disease. Contributing factors for the high prevalence are the increase in obesity and subsequent diabetes combined with an improved long-term survival with diabetes. Environment and genetic variations contribute to DKD susceptibility and progressive loss of kidney function. How the molecular mechanisms of genetic and environmental exposures interact during DKD initiation and progression is the focus of ongoing research efforts. The development of standardized, unbiased high-throughput profiling technologies of human DKD samples opens new avenues in capturing the multiple layers of DKD pathobiology. These techniques routinely interrogate analytes on a genome-wide scale generating comprehensive DKD-associated fingerprints. Linking the molecular fingerprints to deep clinical phenotypes may ultimately elucidate the intricate molecular interplay in a disease stage and subtype-specific manner. This insight will form the basis for accurate prognosis and facilitate targeted therapeutic interventions. In this review, we present ongoing efforts from large-scale data integration translating “-omics” research efforts into improved and individualized health care in DKD.

Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes. Diabetes Care, 27(5), 1047–1053.PubMedCrossRef

Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract, 87(1), 4–14.PubMedCrossRef

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007). Prevalence of chronic kidney disease in the United States. JAMA, 298(17), 2038–2047.PubMedCrossRef

Foley, R., & Collins, A. (2009). The growing economic burden of diabetic kidney disease. Curr Diab Rep, 9(6), 460–465.PubMedCrossRef

The Australia and New Zealand Dialysis and Transplant Registry (2011) The 34th Annual ANZDATA Report 2011—Data to 2010. At: http://wwwanzdataorgau/v1/report_2011html. Accessed March 30, 2012.

European Renal Association—European Dialysis and Transplant (ERA-EDTA) Registry (2011) ERA-EDTA registry annual report 2009. At: http://wwwera-edta-regorg/files/annualreports/pdf/AnnRep2009_newpdf. Accessed March 30, 2012

US Renal Data System (2011) USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. At: http://www.usrds.org. Accessed 22 March 2012.

de Boer, I. H., Rue, T. C., Hall, Y. N., Heagerty, P. J., Weiss, N. S., & Himmelfarb, J. (2011). Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA, 305(24), 2532–2539.PubMedCrossRef

Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med, 339(4), 229–234.PubMedCrossRef

10.

Valmadrid, C. T., Klein, R., Moss, S. E., & Klein, B. E. K. (2000). The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med, 160(8), 1093–1100.PubMedCrossRef

11.

Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., Parfrey, P., Pfeffer, M., Raij, L., Spinosa, D. J., & Wilson, P. W. (2003). Kidney disease as a risk factor for development of cardiovascular disease. Hypertension, 42(5), 1050–1065.PubMedCrossRef

12.

Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813–820.PubMedCrossRef

13.

Forbes, J. M., Fukami, K., & Cooper, M. E. (2007). Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes, 115(2), 69–84.PubMedCrossRef

14.

Figueroa-Romero, C., Sadidi, M., & Feldman, E. (2008). Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord, 9(4), 301–314.PubMedCrossRef

15.

Berthier, C. C., Zhang, H., Schin, M., Henger, A., Nelson, R. G., Yee, B., Boucherot, A., Neusser, M. A., Cohen, C. D., Carter-Su, C., Argetsinger, L. S., Rastaldi, M. P., Brosius, F. C., & Kretzler, M. (2009). Enhanced expression of Janus kinase and signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes, 58(2), 469–477.PubMedCrossRef

16.

Navarro, J. F., & Mora-Fernández, C. (2006). The role of TNF-α in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev, 17(6), 441–450.PubMedCrossRef

17.

Williams, M. E. (2005). Diabetic nephropathy: the proteinuria hypothesis. Am J Nephrol, 25(2), 77–94.PubMedCrossRef

18.

Schena, F. P., & Gesualdo, L. (2005). Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol, 16(3_suppl_1), S30–S33.PubMedCrossRef

19.

Galkina, E., & Ley, K. (2006). Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol, 17(2), 368–377.PubMedCrossRef

20.

Nawroth, P. P., & Isermann, B. (2010). Mechanisms of diabetic nephropathy—old buddies and newcomers part 2. Exp Clin Endocrinol Diabetes, 118(10), 667–672.PubMedCrossRef

21.

Nawroth, P. P., & Isermann, B. (2010). Mechanisms of diabetic nephropathy—old buddies and newcomers part 1. Exp Clin Endocrinol Diabetes, 118(9), 571–576.PubMedCrossRef

22.

Kanwar, Y. S., Sun, L., Xie, P., Liu, F.-Y., & Chen, S. (2011). A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol, 6(1), 395–423.PubMedCrossRef

23.

DiBona, G. F., & Kopp, U. C. (1997). Neural control of renal function. Physiol Rev, 77(1), 75–197.PubMed

24.

Augustyniak, R. A., Tuncel, M., Zhang, W., Toto, R. D., & Victor, R. G. (2002). Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens, 20(1), 3–9.PubMedCrossRef

25.

Grotendorst, G. R. (1997). Connective tissue growth factor: a mediator of TGF-β action on fibroblasts. Cytokine Growth Factor Rev, 8(3), 171–179.PubMedCrossRef

26.

Böttinger, E. P., & Bitzer, M. (2002). TGF-ß signaling in renal disease. J Am Soc Nephrol, 13(10), 2600–2610.PubMedCrossRef

27.

Liu, Y. (2006). Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int, 69(2), 213–217.PubMedCrossRef

28.

Froissart, M., Rossert, J., Jacquot, C., Paillard, M., & Houillier, P. (2005). Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol, 16(3), 763–773.PubMedCrossRef

29.

Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006). Assessing kidney function—measured and estimated glomerular filtration rate. New Engl J Med, 354(23), 2473–2483.PubMedCrossRef

30.

Stevens, L. A., & Levey, A. S. (2009). Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol, 20(11), 2305–2313.PubMedCrossRef

31.

Stevens, L. A., Schmid, C. H., Greene, T., Zhang, Y., Beck, G. J., Froissart, M., Hamm, L. L., Lewis, J. B., Mauer, M., Navis, G. J., Steffes, M. W., Eggers, P. W., Coresh, J., & Levey, A. S. (2010). Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m². Am J Kidney Dis, 56(3), 486–495.PubMedCrossRef

32.

Levey, A. S., Cattran, D., Friedman, A., Miller, W. G., Sedor, J., Tuttle, K., Kasiske, B., & Hostetter, T. (2009). Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis, 54(2), 205–226.PubMedCrossRef

33.

Julian, B. A., Suzuki, H., Suzuki, Y., Tomino, Y., Spasovski, G., & Novak, J. (2009). Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease. Proteomics Clin Appl, 3(9), 1029–1043.PubMedCrossRef

34.

Caramori, M. L., Fioretto, P., & Mauer, M. (2000). The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes, 49(9), 1399–1408.PubMedCrossRef

35.

Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003). Regression of microalbuminuria in type 1 diabetes. New Engl J Med, 348(23), 2285–2293.PubMedCrossRef

36.

Fioretto, P., & Mauer, M. (2007). Histopathology of diabetic nephropathy. Semin Nephrol, 27(2), 195–207.PubMedCrossRef

37.

American Diabetes Association. (2011). Standards of medical care in diabetes—2011. Diabetes Care, 34(Supplement 1), S11–S61.CrossRef

38.

Perkins, B. A., Ficociello, L. H., Ostrander, B. E., Silva, K. H., Weinberg, J., Warram, J. H., & Krolewski, A. S. (2007). Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol, 18(4), 1353–1361.PubMedCrossRef

39.

Perkins, B. A., Ficociello, L. H., Roshan, B., Warram, J. H., & Krolewski, A. S. (2010). In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int, 77(1), 57–64.PubMedCrossRef

40.

MacIsaac, R., & Jerums, G. (2011). Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens, 20(3), 246–257.PubMedCrossRef

41.

Dwyer, J. P., Parving, H. H., Hunsicker, L. G., Ravid, M., Remuzzi, G., & Lewis, J. B. (2012). Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. Cardiorenal Medicine, 2(1), 1–10.PubMedCrossRef

42.

Pavkov, M. E., Knowler, W. C., Lemley, K. V., Mason, C. C., Myers, B. D., & Nelson, R. G. (2012). Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol, 7(1), 78–84.PubMedCrossRef

43.

Karalliedde, J., & Viberti, G. (2010). Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol, 21(12), 2020–2027.PubMedCrossRef

44.

Tryggvason, K., & Pettersson, E. (2003). Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med, 254(3), 216–224.PubMedCrossRef

45.

Iyengar, S. K., Schelling, J. R., & Sedor, J. R. (2002). Approaches to understanding susceptibility to nephropathy: from genetics to genomics. Kidney Int, 61(Suppl. 1), S61–S67.PubMedCrossRef

46.

Iyengar, S. K., Abboud, H. E., Goddard, K. A. B., Saad, M. F., Adler, S. G., Arar, N. H., Bowden, D. W., Duggirala, R., Elston, R. C., Hanson, R. L., Ipp, E., Kao, W. H. L., Kimmel, P. L., Klag, M. J., Knowler, W. C., Meoni, L. A., Nelson, R. G., Nicholas, S. B., Pahl, M. V., Parekh, R. S., Quade, S. R. E., Rich, S. S., Rotter, J. I., Scavini, M., Schelling, J. R., Sedor, J. R., Sehgal, A. R., Shah, V. O., Smith, M. W., Taylor, K. D., Winkler, C. A., Zager, P. G., & Freedman, B. I. (2007). Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The Family Investigation of Nephropathy and Diabetes (FIND). Diabetes, 56(6), 1577–1585.PubMedCrossRef

47.

Igo, J. R. P., Iyengar, S. K., Nicholas, S. B., Goddard, K. A. B., Langefeld, C. D., Hanson, R. L., Duggirala, R., Divers, J., Abboud, H., Adler, S. G., Arar, N. H., Horvath, A., Elston, R. C., Bowden, D. W., Guo, X., Ipp, E., Kao, W. H. L., Kimmel, P. L., Knowler, W. C., Meoni, L. A., Molineros, J., Nelson, R. G., Pahl, M. V., Parekh, R. S., Rasooly, R. S., Schelling, J. R., Shah, V. O., Smith, M. W., Winkler, C. A., Zager, P. G., Sedor, J. R., Freedman, B. I., & The Family Investigation of Nephropathy and Diabetes Research Group. (2011). Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol., 33(5), 381–389.PubMedCrossRef

48.

Gohda, T., Tanimoto, M., Watanabe-Yamada, K., Matsumoto, M., Kaneko, S., Hagiwara, S., Shiina, K., Shike, T., Funabiki, K., & Tomino, Y. (2005). Genetic susceptibility to type 2 diabetic nephropathy in human and animal models. Nephrology, 10(Supplement s2), S22–S25.PubMedCrossRef

49.

Tanaka, N., & Babazono, T. (2005). Assessing genetic susceptibility to diabetic nephropathy. Nephrology, 10(Supplement s2), S17–S21.PubMedCrossRef

50.

Mueller, P. W., Rogus, J. J., Cleary, P. A., Zhao, Y., Smiles, A. M., Steffes, M. W., Bucksa, J., Gibson, T. B., Cordovado, S. K., Krolewski, A. S., Nierras, C. R., & Warram, J. H. (2006). Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol, 17(7), 1782–1790.PubMedCrossRef

51.

Freedman, B. I., Bostrom, M., Daeihagh, P., & Bowden, D. W. (2007). Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol, 2(6), 1306–1316.PubMedCrossRef

52.

Conway, B. R., & Maxwell, A. P. (2009). Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron Clin Pract, 112(4), c213–c221.PubMedCrossRef

53.

Pezzolesi, M. G., Poznik, G. D., Mychaleckyj, J. C., Paterson, A. D., Barati, M. T., Klein, J. B., Ng, D. P. K., Placha, G., Canani, L. H., Bochenski, J., Waggott, D., Merchant, M. L., Krolewski, B., Mirea, L., Wanic, K., Katavetin, P., Kure, M., Wolkow, P., Dunn, J. S., Smiles, A., Walker, W. H., Boright, A. P., Bull, S. B., the DCCT/EDIC Research Group, Doria, A., Rogus, J. J., Rich, S. S., Warram, J. H., & Krolewski, A. S. (2009). Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes, 58(6), 1403–1410.PubMedCrossRef

54.

Pezzolesi, M. G., Skupien, J., Mychaleckyj, J. C., Warram, J. H., & Krolewski, A. S. (2010). Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD Collection. Semin Nephrol, 30(2), 126–140.PubMedCrossRef

55.

Schadt, E. E., Sachs, A., & Friend, S. (2005). Embracing complexity, inching closer to reality. Sci STKE, 2005(295), pe40.PubMedCrossRef

56.

Dobrin, R., Zhu, J., Molony, C., Argman, C., Parrish, M., Carlson, S., Allan, M., Pomp, D., & Schadt, E. (2009). Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome Biol, 10(5), R55.PubMedCrossRef

57.

Sauer, U., Heinemann, M., & Zamboni, N. (2007). Getting closer to the whole picture. Science, 316(5824), 550–551.PubMedCrossRef

58.

Chuang, H.-Y., Hofree, M., & Ideker, T. (2010). A decade of systems biology. Annu Rev Cell Dev Biol, 26(1), 721–744.PubMedCrossRef

59.

Houle, D., Govindaraju, D. R., & Omholt, S. (2010). Phenomics: the next challenge. Nat Rev Genet, 11(12), 855–866.PubMedCrossRef

60.

Haring, R., and Wallaschofski, H. (2012) Diving through the “-Omics”: the case for deep phenotyping and systems epidemiology. OMICS: J Integrative Biol 16 (in press) (Epub ahead of print: February 9, 2012).

61.

Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310(5748), 644–648.PubMedCrossRef

62.

Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. New Engl J Med, 363(4), 301–304.PubMedCrossRef

63.

Allison, M. (2008). Is personalized medicine finally arriving? Nat Biotechnol, 26(5), 509–517.PubMedCrossRef

64.

Seaquist, E. R., Goetz, F. C., Rich, S., & Barbosa, J. (1989). Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. New Engl J Med, 320(18), 1161–1165.PubMedCrossRef

65.

Borch-Johnsen, K., Norgaard, K., Hommel, E., Mathiesen, E. R., Jensen, J. S., Deckert, T., & Parving, H.-H. (1992). Is diabetic nephropathy an inherited complication? Kidney Int, 41(4), 719–722.PubMedCrossRef

66.

Imperatore, G., Knowler, W. C., Pettitt, D. J., Kobes, S., Bennett, P. H., & Hanson, R. L. (2000). Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes, 49(6), 1049–1056.PubMedCrossRef

67.

Knowler, W. C., Coresh, J., Elston, R. C., Freedman, B. I., Iyengar, S. K., Kimmel, P. L., Olson, J. M., Plaetke, R., Sedor, J. R., & Seldin, M. F. (2005). The Family Investigation of Nephropathy and Diabetes (FIND): design and methods. J Diabetes Complications, 19(1), 1–9.PubMedCrossRef

68.

Pezzolesi, M. G., Poznik, G. D., Skupien, J., Smiles, A. M., Mychaleckyj, J. C., Rich, S. S., Warram, J. H., & Krolewski, A. S. (2011). An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes. Kidney Int, 80(1), 105–111.PubMedCrossRef

69.

Mooyaart, A., Valk, E., van Es, L., Bruijn, J., de Heer, E., Freedman, B., Dekkers, O., & Baelde, H. (2011). Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia, 54(3), 544–553.PubMedCrossRef

70.

Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., Cho, J. H., Guttmacher, A. E., Kong, A., Kruglyak, L., Mardis, E., Rotimi, C. N., Slatkin, M., Valle, D., Whittemore, A. S., Boehnke, M., Clark, A. G., Eichler, E. E., Gibson, G., Haines, J. L., Mackay, T. F. C., McCarroll, S. A., & Visscher, P. M. (2009). Finding the missing heritability of complex diseases. Nature, 461(7265), 747–753.PubMedCrossRef

71.

Zuk, O., Hechter, E., Sunyaev, S. R., & Lander, E. S. (2012). The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci USA, 109(4), 1193–1198.PubMedCrossRef

72.

McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008). Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet, 9(5), 356–369.PubMedCrossRef

73.

Genovese, G., Friedman, D. J., Ross, M. D., Lecordier, L., Uzureau, P., Freedman, B. I., Bowden, D. W., Langefeld, C. D., Oleksyk, T. K., Uscinski Knob, A. L., Bernhardy, A. J., Hicks, P. J., Nelson, G. W., Vanhollebeke, B., Winkler, C. A., Kopp, J. B., Pays, E., & Pollak, M. R. (2010). Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science, 329(5993), 841–845.PubMedCrossRef

74.

Lusis, A. J. (2012). Life after GWAS. Atertio Thromb Vasc Biol, 32(2), 169–169.CrossRef

75.

Pomerantz, M. M., Ahmadiyeh, N., Jia, L., Herman, P., Verzi, M. P., Doddapaneni, H., Beckwith, C. A., Chan, J. A., Hills, A., Davis, M., Yao, K., Kehoe, S. M., Lenz, H.-J., Haiman, C. A., Yan, C., Henderson, B. E., Frenkel, B., Barretina, J., Bass, A., Tabernero, J., Baselga, J., Regan, M. M., Manak, J. R., Shivdasani, R., Coetzee, G. A., & Freedman, M. L. (2009). The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet, 41(8), 882–884.PubMedCrossRef

76.

Pearson, E. R. (2009). Pharmacogenetics in diabetes. Curr Diab Rep, 9(2), 172–181.PubMedCrossRef

77.

McCarthy, M. I. (2010). Genomics, type 2 diabetes, and obesity. New Engl J Med, 363(24), 2339–2350.PubMedCrossRef

78.

The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med, 329(14), 977–986.CrossRef

79.

UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837–853.CrossRef

80.

Engerman, R. L., & Kern, T. S. (1987). Progression of incipient diabetic retinopathy during good glycemic control. Diabetes, 36(7), 808–812.PubMedCrossRef

81.

Ihnat, M. A., Thorpe, J. E., & Ceriello, A. (2007). Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med, 24(6), 582–586.PubMedCrossRef

82.

El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E., & Brownlee, M. (2008). Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med, 205(10), 2409–2417.PubMedCrossRef

83.

Feinberg, A. P. (2008). Epigenetics at the epicenter of modern medicine. JAMA, 299(11), 1345–1350.PubMedCrossRef

84.

Ceriello, A., Ihnat, M. A., & Thorpe, J. E. (2009). The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab, 94(2), 410–415.PubMedCrossRef

85.

Dwivedi, R. S., Herman, J. G., McCaffrey, T. A., & Raj, D. S. C. (2011). Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int, 79(1), 23–32.PubMedCrossRef

86.

Reddy, M. A., & Natarajan, R. (2011). Epigenetics in diabetic kidney disease. J Am Soc Nephrol, 22(12), 2182–2185.PubMedCrossRef

87.

Villeneuve, L. M., & Natarajan, R. (2010). Epigenetics of diabetic complications. Expert Rev Endocrinol Metab, 5(1), 137–148.

88.

Pirola, L., Balcerczyk, A., Okabe, J., & El-Osta, A. (2010). Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol, 6(12), 665–675.PubMedCrossRef

89.

Mohtat, D., & Susztak, K. (2010). Fine tuning gene expression: the epigenome. Semin Nephrol, 30(5), 468–476.PubMedCrossRef

90.

Reddy, M. A., & Natarajan, R. (2011). Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res, 90(3), 421–429.PubMedCrossRef

91.

Thomas, M. C., Groop, P.-H., & Tryggvason, K. (2012). Towards understanding the inherited susceptibility for nephropathy in diabetes. Curr Opin Nephrol Hypertens, 21(2), 195–202.PubMedCrossRef

92.

Wetterstrand, K. (2012) DNA sequencing costs: data from the NHGRI Large-Scale Genome Sequencing Program. Available at: http://wwwgenomegov/sequencingcosts. Accessed March 20, 2012.

93.

Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 270(5235), 467–470.PubMedCrossRef

94.

Kretzler, M., Cohen, C. D., Doran, P., Henger, A., Madden, S., Gröne, E. F., Nelson, P. J., Schlöndorff, D., & Gröne, H.-J. (2002). Repuncturing the renal biopsy: strategies for molecular diagnosis in nephrology. J Am Soc Nephrol, 13(7), 1961–1972.PubMedCrossRef

95.

Cohen, C. D., Frach, K., Schlondorff, D., & Kretzler, M. (2002). Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int, 61(1), 133–140.PubMedCrossRef

96.

Schmid, H., Henger, A., Cohen, C. D., Frach, K., Gröne, H.-J., Schlöndorff, D., & Kretzler, M. (2003). Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc Nephrol, 14(11), 2958–2966.PubMedCrossRef

97.

Kieran, N. E., Doran, P. P., Connolly, S. B., Greenan, M.-C., Higgins, D. F., Leonard, M., Godson, C., Taylor, C. T., Henger, A., Kretzler, M., Burne, M. J., Rabb, H., & Brady, H. R. (2003). Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int, 64(2), 480–492.PubMedCrossRef

98.

Henger, A., Kretzler, M., Doran, P., Bonrouhi, M., Schmid, H., Kiss, E., Cohen, C. D., Madden, S., Porubsky, S., Grone, E. F., Schlondorff, D., Nelson, P. J., & Grone, H.-J. (2004). Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int, 65(3), 904–917.PubMedCrossRef

99.

Baelde, H. J., Eikmans, M., Doran, P. P., Lappin, D. W. P., de Heer, E., & Bruijn, J. A. (2004). Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis, 43(4), 636–650.PubMedCrossRef

100.

Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., Nitsche, A., Kiss, E., Bleich, M., Gröne, H.-J., Nelson, P. J., Schlöndorff, D., Cohen, C. D., & Kretzler, M. (2006). Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy. Diabetes, 55(11), 2993–3003.PubMedCrossRef

101.

Lindenmeyer, M. T., Kretzler, M., Boucherot, A., Berra, S., Yasuda, Y., Henger, A., Eichinger, F., Gaiser, S., Schmid, H., Rastaldi, M. P., Schrier, R. W., Schlondorff, D., & Cohen, C. D. (2007). Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol, 18(6), 1765–1776.PubMedCrossRef

102.

Woroniecka, K. I., Park, A. S. D., Mohtat, D., Thomas, D. B., Pullman, J. M., & Susztak, K. (2011). Transcriptome analysis of human diabetic kidney disease. Diabetes, 60(9), 2354–2369.PubMedCrossRef

103.

Lin, Y. L., Peng, S. J., Ferng, S. H., Tzen, C. Y., & Yang, C. S. (2009). Clinical indicators which necessitate renal biopsy in type 2 diabetes mellitus patients with renal disease. Int J Clin Pract, 63(8), 1167–1176.PubMedCrossRef

104.

Mauer, S. M., Steffes, M. W., Ellis, E. N., Sutherland, D. E., Brown, D. M., & Goetz, F. C. (1984). Structural-functional relationships in diabetic nephropathy. J Clin Invest, 74(4), 1143–1155.PubMedCrossRef

105.

Pagtalunan, M. E., Miller, P. L., Jumping-Eagle, S., Nelson, R. G., Myers, B. D., Rennke, H. G., Coplon, N. S., Sun, L., & Meyer, T. W. (1997). Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest, 99(2), 342–348.PubMedCrossRef

106.

Moutzouris, D.-A., Herlitz, L., Appel, G. B., Markowitz, G. S., Freudenthal, B., Radhakrishnan, J., & D’Agati, V. D. (2009). Renal biopsy in the very elderly. Clin J Am Soc Nephrol, 4(6), 1073–1082.PubMedCrossRef

107.

Zhang, P.-P., Ge, Y.-C., Li, S.-J., Xie, H.-L., Li, L.-S., & Liu, Z.-H. (2011). Renal biopsy in type 2 diabetes: timing of complications and evaluating of safety in Chinese patients. Nephrology, 16(1), 100–105.PubMedCrossRef

108.

Cohen, C. D., Grone, H.-J., Grone, E. F., Nelson, P. J., Schlondorff, D., & Kretzler, M. (2002). Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue. Kidney Int, 61(1), 125–132.PubMedCrossRef

109.

Hodgin, J. B., Borczuk, A. C., Nasr, S. H., Markowitz, G. S., Nair, V., Martini, S., Eichinger, F., Vining, C., Berthier, C. C., Kretzler, M., & D’Agati, V. D. (2010). A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol, 177(4), 1674–1686.PubMedCrossRef

110.

Shen-Orr, S. S., Tibshirani, R., Khatri, P., Bodian, D. L., Staedtler, F., Perry, N. M., Hastie, T., Sarwal, M. M., Davis, M. M., & Butte, A. J. (2010). Cell type-specific gene expression differences in complex tissues. Nat Methods, 7(4), 287–289.PubMedCrossRef

111.

Kaiser, J. (2012). Biomarker tests need closer scrutiny, IOM concludes. Science, 335(6076), 1554–1554.PubMedCrossRef

112.

Consensus Report Institute of Medicine (2012) Evolution of translational OMICS: lessons learned and the path forward. At: http://wwwiomedu/Reports/2012/Evolution-of-Translational-Omics.aspx. Accessed March 23, 2012

113.

Gygi, S. P., Rochon, Y., Franza, B. R., & Aebersold, R. (1999). Correlation between protein and mRNA abundance in yeast. Mol Cell Biol, 19(3), 1720–1730.PubMed

114.

Cravatt, B. F., Simon, G. M., & Yates Iii, J. R. (2007). The biological impact of mass-spectrometry-based proteomics. Nature, 450(7172), 991–1000.PubMedCrossRef

115.

Vogel, C., & Marcotte, E. M. (2012). Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet, 13(4), 227–232.PubMed

116.

Sébédio, J.-L., Pujos-Guillot, E., & Ferrara, M. (2009). Metabolomics in evaluation of glucose disorders. Curr Opin Clin Nutr Metab Care, 12(4), 412–418.PubMedCrossRef

117.

Wang, J. H., Byun, J., & Pennathur, S. (2010). Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol, 30(5), 500–511.PubMedCrossRef

118.

Ben Ameur, R., Molina, L., Bolvin, C., Kifagi, C., Jarraya, F., Ayadi, H., Molina, F., & Granier, C. (2010). Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant, 25(9), 2866–2875.PubMedCrossRef

119.

Thongboonkerd, V. (2011). Study of diabetic nephropathy in the proteomic era. Contrib Nephrol, 170, 172–183.PubMedCrossRef

120.

Mäkinen, V.-P., Tynkkynen, T., Soininen, P., Peltola, T., Kangas, A. J., Forsblom, C., Thorn, L. M., Kaski, K., Laatikainen, R., Ala-Korpela, M., & Groop, P.-H. (2012). Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res, 11(3), 1782–1790.PubMedCrossRef

121.

Thongboonkerd, V., & Malasit, P. (2005). Renal and urinary proteomics: current applications and challenges. Proteomics, 5(4), 1033–1042.PubMedCrossRef

122.

Decramer, S., de Peredo, A. G., Breuil, B., Mischak, H., Monsarrat, B., Bascands, J.-L., & Schanstra, J. P. (2008). Urine in clinical proteomics. Mol Cell Proteomics, 7(10), 1850–1862.PubMedCrossRef

123.

Rossing, K., Mischak, H., Dakna, M., Zurbig, P., Novak, J., Julian, B. A., Good, D. M., Coon, J. J., Tarnow, L., Rossing, P., & on behalf of the PREDICTIONS Network. (2008). Urinary proteomics in diabetes and CKD. J Am Soc Nephrol, 19(7), 1283–1290.PubMedCrossRef

124.

Merchant, M. L., Perkins, B. A., Boratyn, G. M., Ficociello, L. H., Wilkey, D. W., Barati, M. T., Bertram, C. C., Page, G. P., Rovin, B. H., Warram, J. H., Krolewski, A. S., & Klein, J. B. (2009). Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol, 20(9), 2065–2074.PubMedCrossRef

125.

Otu, H. H., Can, H., Spentzos, D., Nelson, R. G., Hanson, R. L., Looker, H. C., Knowler, W. C., Monroy, M., Libermann, T. A., Karumanchi, S. A., & Thadhani, R. (2007). Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care, 30(3), 638–643.PubMedCrossRef

126.

Overgaard, A., Hansen, H., Lajer, M., Pedersen, L., Tarnow, L., Rossing, P., McGuire, J., & Pociot, F. (2010). Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci, 8(1), 4.PubMedCrossRef

127.

Overgaard, A. J., Thingholm, T. E., Larsen, M. R., Tarnow, L., Rossing, P., McGuire, J. N., & Pociot, F. (2010). Quantitative iTRAQ-based proteomic identification of candidate biomarkers for diabetic nephropathy in plasma of type 1 diabetic patients. Clin Proteomics, 6(4), 105–114.PubMedCrossRef

128.

Coon, J. J., Zürbig, P., Dakna, M., Dominiczak, A. F., Decramer, S., Fliser, D., Frommberger, M., Golovko, I., Good, D. M., Herget-Rosenthal, S., Jankowski, J., Julian, B. A., Kellmann, M., Kolch, W., Massy, Z., Novak, J., Rossing, K., Schanstra, J. P., Schiffer, E., Theodorescu, D., Vanholder, R., Weissinger, E. M., Mischak, H., & Schmitt-Kopplin, P. (2008). CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl, 2(7–8), 964–973.PubMedCrossRef

129.

Jantos-Siwy, J., Schiffer, E., Brand, K., Schumann, G., Rossing, K., Delles, C., Mischak, H., & Metzger, J. (2009). Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res, 8(1), 268–281.PubMedCrossRef

130.

Maahs, D. M., Siwy, J., Argilés, À., Cerna, M., Delles, C., Dominiczak, A. F., Gayrard, N., Iphöfer, A., Jänsch, L., Jerums, G., Medek, K., Mischak, H., Navis, G. J., Roob, J. M., Rossing, K., Rossing, P., Rychlík, I., Schiffer, E., Schmieder, R. E., Wascher, T. C., Winklhofer-Roob, B. M., Zimmerli, L. U., Zürbig, P., & Snell-Bergeon, J. K. (2010). Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS ONE, 5(9), e13051.PubMedCrossRef

131.

Alkhalaf, A., Zürbig, P., Bakker, S. J. L., Bilo, H. J. G., Cerna, M., Fischer, C., Fuchs, S., Janssen, B., Medek, K., Mischak, H., Roob, J. M., Rossing, K., Rossing, P., Rychlík, I., Sourij, H., Tiran, B., Winklhofer-Roob, B. M., Navis, G. J., & for the PREDICTIONS Group. (2010). Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE, 5(10), e13421.PubMedCrossRef

132.

Good, D. M., Zurbig, P., Argiles, A., Bauer, H. W., Behrens, G., Coon, J. J., Dakna, M., Decramer, S., Delles, C., Dominiczak, A. F., Ehrich, J. H. H., Eitner, F., Fliser, D., Frommberger, M., Ganser, A., Girolami, M. A., Golovko, I., Gwinner, W., Haubitz, M., Herget-Rosenthal, S., Jankowski, J., Jahn, H., Jerums, G., Julian, B. A., Kellmann, M., Kliem, V., Kolch, W., Krolewski, A. S., Luppi, M., Massy, Z., Melter, M., Neususs, C., Novak, J., Peter, K., Rossing, K., Rupprecht, H., Schanstra, J. P., Schiffer, E., Stolzenburg, J.-U., Tarnow, L., Theodorescu, D., Thongboonkerd, V., Vanholder, R., Weissinger, E. M., Mischak, H., & Schmitt-Kopplin, P. (2010). Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics, 9(11), 2424–2437.PubMedCrossRef

133.

Jain, S., Rajput, A., Kumar, Y., Uppuluri, N., Arvind, A. S., & Tatu, U. (2005). Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India, 53(June), 513–520.PubMed

134.

Fisher, W. G., Lucas, J. E., Mehdi, U. F., Qunibi, D. W., Garner, H. R., Rosenblatt, K. P., & Toto, R. D. (2011). A method for isolation and identification of urinary biomarkers in patients with diabetic nephropathy. Proteomics Clin Appl, 5(11–12), 603–612.PubMedCrossRef

135.

Lowe, J. B. (2001). Glycosylation, immunity, and autoimmunity. Cell, 104(6), 809–812.PubMedCrossRef

136.

Yang, N., Feng, S., Shedden, K., Xie, X., Liu, Y., Rosser, C. J., Lubman, D. M., & Goodison, S. (2011). Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res, 17(10), 3349–3359.PubMedCrossRef

137.

Ahn, J.-M., Kim, B.-G., Yu, M.-H., Lee, I.-K., & Cho, J.-Y. (2010). Identification of diabetic nephropathy-selective proteins in human plasma by multi-lectin affinity chromatography and LC-MS/MS. Proteomics Clin Appl, 4(6–7), 644–653.PubMedCrossRef

138.

Vivekanandan-Giri, A., Slocum, J. L., Buller, C. L., Basrur, V., Ju, W., Pop-Busui, R., et al. (2011). Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics, 2011, 18. Article ID 214715.

139.

Pisitkun, T., Shen, R.-F., & Knepper, M. A. (2004). Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA, 101(36), 13368–13373.PubMedCrossRef

140.

Gonzales, P. A., Pisitkun, T., Hoffert, J. D., Tchapyjnikov, D., Star, R. A., Kleta, R., Wang, N. S., & Knepper, M. A. (2009). Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol, 20(2), 363–379.PubMedCrossRef

141.

Konvalinka, A., Scholey, J. W., & Diamandis, E. P. (2012). Searching for new biomarkers of renal diseases through proteomics. Clin Chem, 58(2), 353–365.PubMedCrossRef

142.

Mischak, H., Apweiler, R., Banks, R. E., Conaway, M., Coon, J., Dominiczak, A., Ehrich, J. H. H., Fliser, D., Girolami, M., Hermjakob, H., Hochstrasser, D., Jankowski, J., Julian, B. A., Kolch, W., Massy, Z. A., Neusuess, C., Novak, J., Peter, K., Rossing, K., Schanstra, J., Semmes, O. J., Theodorescu, D., Thongboonkerd, V., Weissinger, E. M., Van Eyk, J. E., & Yamamoto, T. (2007). Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl, 1(2), 148–156.PubMedCrossRef

143.

Good, D. M., Thongboonkerd, V., Novak, J., Bascands, J.-L., Schanstra, J. P., Coon, J. J., Dominiczak, A., & Mischak, H. (2007). Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res, 6(12), 4549–4555.PubMedCrossRef

144.

Kinsinger, C. R., Apffel, J., Baker, M., Bian, X., Borchers, C. H., Bradshaw, R., Brusniak, M.-Y., Chan, D. W., Deutsch, E. W., Domon, B., Gorman, J., Grimm, R., Hancock, W., Hermjakob, H., Horn, D., Hunter, C., Kolar, P., Kraus, H.-J., Langen, H., Linding, R., Moritz, R. L., Omenn, G. S., Orlando, R., Pandey, A., Ping, P., Rahbar, A., Rivers, R., Seymour, S. L., Simpson, R. J., Slotta, D., Smith, R. D., Stein, S. E., Tabb, D. L., Tagle, D., Yates, J. R., & Rodriguez, H. (2011). Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles). Proteomics Clin Appl, 5(11–12), 580–589.PubMedCrossRef

145.

Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, J., Ansorge, W., Ball, C. A., Causton, H. C., Gaasterland, T., Glenisson, P., Holstege, F. C. P., Kim, I. F., Markowitz, V., Matese, J. C., Parkinson, H., Robinson, A., Sarkans, U., Schulze-Kremer, S., Stewart, J., Taylor, R., Vilo, J., & Vingron, M. (2001). Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. Nat Genet, 29(4), 365–371.PubMedCrossRef

146.

Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., Nyati, M. K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G. S., Ghosh, D., Pennathur, S., Alexander, D. C., Berger, A., Shuster, J. R., Wei, J. T., Varambally, S., Beecher, C., & Chinnaiyan, A. M. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457(7231), 910–914.PubMedCrossRef

147.

Kim, K., Aronov, P., Zakharkin, S. O., Anderson, D., Perroud, B., Thompson, I. M., & Weiss, R. H. (2009). Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics, 8(3), 558–570.PubMedCrossRef

148.

Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., Rochon, J., Gallup, D., Ilkayeva, O., Wenner, B. R., Yancy, W. S., Jr., Eisenson, H., Musante, G., Surwit, R. S., Millington, D. S., Butler, M. D., & Svetkey, L. P. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism, 9(4), 311–326.PubMedCrossRef

149.

Suhre, K., Meisinger, C., Döring, A., Altmaier, E., Belcredi, P., Gieger, C., Chang, D., Milburn, M. V., Gall, W. E., Weinberger, K. M., Mewes, H.-W., Hrabé de Angelis, M., Wichmann, H. E., Kronenberg, F., Adamski, J., & Illig, T. (2010). Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE, 5(11), e13953.PubMedCrossRef

150.

Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., O’Donnell, C. J., Carr, S. A., Mootha, V. K., Florez, J. C., Souza, A., Melander, O., Clish, C. B., & Gerszten, R. E. (2011). Metabolite profiles and the risk of developing diabetes. Nat Med, 17(4), 448–453.PubMedCrossRef

151.

Rhee, E. P., Cheng, S., Larson, M. G., Walford, G. A., Lewis, G. D., McCabe, E., Yang, E., Farrell, L., Fox, C. S., O’Donnell, C. J., Carr, S. A., Vasan, R. S., Florez, J. C., Clish, C. B., Wang, T. J., & Gerszten, R. E. (2011). Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest, 121(4), 1402–1411.PubMedCrossRef

152.

Ganti, S., & Weiss, R. H. (2011). Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol, 29(5), 551–557.PubMedCrossRef

153.

Rhee, E. P., & Gerszten, R. E. (2012). Metabolomics and cardiovascular biomarker discovery. Clin Chem, 58(1), 139–147.PubMedCrossRef

154.

Weiss, R. H., & Kim, K. (2012). Metabolomics in the study of kidney diseases. Nat Rev Nephrol, 8(1), 22–33.CrossRef

155.

Zhang, H., Saha, J., Byun, J., Schin, M., Lorenz, M., Kennedy, R. T., Kretzler, M., Feldman, E. L., Pennathur, S., & Brosius, F. C. (2008). Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol, 295(4), F1071–F1081.PubMedCrossRef

156.

Smith, C. A., Maille, G. O., Want, E. J., Qin, C., Trauger, S. A., Brandon, T. R., Custodio, D. E., Abagyan, R., & Siuzdak, G. (2005). METLIN: a metabolite mass spectral database. Ther Drug Monit, 27(6), 747–751.PubMedCrossRef

157.

Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S., Fung, C., Nikolai, L., Lewis, M., Coutouly, M.-A., Forsythe, I., Tang, P., Shrivastava, S., Jeroncic, K., Stothard, P., Amegbey, G., Block, D., Hau, D. D., Wagner, J., Miniaci, J., Clements, M., Gebremedhin, M., Guo, N., Zhang, Y., Duggan, G. E., MacInnis, G. D., Weljie, A. M., Dowlatabadi, R., Bamforth, F., Clive, D., Greiner, R., Li, L., Marrie, T., Sykes, B. D., Vogel, H. J., & Querengesser, L. (2007). HMDB: the Human Metabolome Database. NAR, 35(suppl 1), D521–D526.PubMedCrossRef

158.

Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., Massy, Z. A., & on behalf of the European Uremic Toxin Work Group. (2009). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol, 4(10), 1551–1558.PubMedCrossRef

159.

Zhang, J., Yan, L., Chen, W., Lin, L., Song, X., Yan, X., Hang, W., & Huang, B. (2009). Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC–oaTOF-MS system. Anal Chim Acta, 650(1), 16–22.PubMedCrossRef

160.

van der Kloet, F., Tempels, F., Ismail, N., van der Heijden, R., Kasper, P., Rojas-Cherto, M., van Doorn, R., Spijksma, G., Koek, M., van der Greef, J., Mäkinen, V., Forsblom, C., Holthöfer, H., Groop, P., Reijmers, T., & Hankemeier, T. (2012). Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics, 8(1), 109–119.PubMedCrossRef

161.

Xia, J.-F., Liang, Q.-L., Liang, X.-P., Wang, Y.-M., Hu, P., Li, P., & Luo, G.-A. (2009). Ultraviolet and tandem mass spectrometry for simultaneous quantification of 21 pivotal metabolites in plasma from patients with diabetic nephropathy. J Chromatogr B Analyt Technol Biomed Life Sci, 877(20–21), 1930–1936.PubMed

162.

Sieberts, S., & Schadt, E. E. (2007). Moving toward a system genetics view of disease. Mamm Genome, 18(6), 389–401.PubMedCrossRef

163.

Emilsson, V., Thorleifsson, G., Zhang, B., Leonardson, A. S., Zink, F., Zhu, J., Carlson, S., Helgason, A., Walters, G. B., Gunnarsdottir, S., Mouy, M., Steinthorsdottir, V., Eiriksdottir, G. H., Bjornsdottir, G., Reynisdottir, I., Gudbjartsson, D., Helgadottir, A., Jonasdottir, A., Jonasdottir, A., Styrkarsdottir, U., Gretarsdottir, S., Magnusson, K. P., Stefansson, H., Fossdal, R., Kristjansson, K., Gislason, H. G., Stefansson, T., Leifsson, B. G., Thorsteinsdottir, U., Lamb, J. R., Gulcher, J. R., Reitman, M. L., Kong, A., Schadt, E. E., & Stefansson, K. (2008). Genetics of gene expression and its effect on disease. Nature, 452(7186), 423–428.PubMedCrossRef

164.

Ioannidis, J. P. A., Thomas, G., & Daly, M. J. (2009). Validating, augmenting and refining genome-wide association signals. Nat Rev Genet, 10(5), 318–329.PubMedCrossRef

165.

Keurentjes, J. J. B., Fu, J., de Vos, C. H. R., Lommen, A., Hall, R. D., Bino, R. J., van der Plas, L. H. W., Jansen, R. C., Vreugdenhil, D., & Koornneef, M. (2006). The genetics of plant metabolism. Nat Genet, 38(7), 842–849.PubMedCrossRef

166.

Gieger, C., Geistlinger, L., Altmaier, E., Hrabé de Angelis, M., Kronenberg, F., Meitinger, T., Mewes, H.-W., Wichmann, H. E., Weinberger, K. M., Adamski, J., Illig, T., & Suhre, K. (2008). Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet, 4(11), e1000282.PubMedCrossRef

167.

Ferrara, C. T., Wang, P., Neto, E. C., Stevens, R. D., Bain, J. R., Wenner, B. R., Ilkayeva, O. R., Keller, M. P., Blasiole, D. A., Kendziorski, C., Yandell, B. S., Newgard, C. B., & Attie, A. D. (2008). Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet, 4(3), e1000034.PubMedCrossRef

168.

Shah, S. H., Hauser, E. R., Bain, J. R., Muehlbauer, M. J., Haynes, C., Stevens, R. D., et al. (2009). High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol, 5, 258.PubMedCrossRef

169.

Suhre, K., Wallaschofski, H., Raffler, J., Friedrich, N., Haring, R., Michael, K., Wasner, C., Krebs, A., Kronenberg, F., Chang, D., Meisinger, C., Wichmann, H. E., Hoffmann, W., Volzke, H., Volker, U., Teumer, A., Biffar, R., Kocher, T., Felix, S. B., Illig, T., Kroemer, H. K., Gieger, C., Romisch-Margl, W., & Nauck, M. (2011). A genome-wide association study of metabolic traits in human urine. Nat Genet, 43(6), 565–569.PubMedCrossRef

170.

Daly, A. K. (2010). Drug-induced liver injury: past, present and future. Pharmacogenomics, 11(5), 607–611.PubMedCrossRef

171.

Zurück zum Zitat Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., Johansen, C. T., Fouchier, S. W., Isaacs, A., Peloso, G. M., Barbalic, M., Ricketts, S. L., Bis, J. C., Aulchenko, Y. S., Thorleifsson, G., Feitosa, M. F., Chambers, J., Orho-Melander, M., Melander, O., Johnson, T., Li, X., Guo, X., Li, M., Shin Cho, Y., Jin Go, M., Jin Kim, Y., Lee, J.-Y., Park, T., Kim, K., Sim, X., Twee-Hee Ong, R., Croteau-Chonka, D. C., Lange, L. A., Smith, J. D., Song, K., Hua Zhao, J., Yuan, X., Luan, J. A., Lamina, C., Ziegler, A., Zhang, W., Zee, R. Y. L., Wright, A. F., Witteman, J. C. M., Wilson, J. F., Willemsen, G., Wichmann, H. E., Whitfield, J. B., Waterworth, D. M., Wareham, N. J., Waeber, G., Vollenweider, P., Voight, B. F., Vitart, V., Uitterlinden, A. G., Uda, M., Tuomilehto, J., Thompson, J. R., Tanaka, T., Surakka, I., Stringham, H. M., Spector, T. D., Soranzo, N., Smit, J. H., Sinisalo, J., Silander, K., Sijbrands, E. J. G., Scuteri, A., Scott, J., Schlessinger, D., Sanna, S., Salomaa, V., Saharinen, J., Sabatti, C., Ruokonen, A., Rudan, I., Rose, L. M., Roberts, R., Rieder, M., Psaty, B. M., Pramstaller, P. P., Pichler, I., Perola, M., Penninx, B. W. J. H., Pedersen, N. L., Pattaro, C., Parker, A. N., Pare, G., Oostra, B. A., O’Donnell, C. J., Nieminen, M. S., Nickerson, D. A., Montgomery, G. W., Meitinger, T., McPherson, R., McCarthy, M. I., McArdle, W., Masson, D., Martin, N. G., Marroni, F., Mangino, M., Magnusson, P. K. E., Lucas, G., Luben, R., Loos, R. J. F., Lokki, M.-L., Lettre, G., Langenberg, C., Launer, L. J., Lakatta, E. G., Laaksonen, R., Kyvik, K. O., Kronenberg, F., Konig, I. R., Khaw, K.-T., Kaprio, J., Kaplan, L. M., Johansson, A., Jarvelin, M.-R., Cecile, J. W., Janssens, A., Ingelsson, E., Igl, W., Kees Hovingh, G., Hottenga, J.-J., Hofman, A., Hicks, A. A., Hengstenberg, C., Heid, I. M., Hayward, C., Havulinna, A. S., Hastie, N. D., Harris, T. B., Haritunians, T., Hall, A. S., Gyllensten, U., Guiducci, C., Groop, L. C., Gonzalez, E., Gieger, C., Freimer, N. B., Ferrucci, L., Erdmann, J., Elliott, P., Ejebe, K. G., Doring, A., Dominiczak, A. F., Demissie, S., Deloukas, P., de Geus, E. J. C., de Faire, U., Crawford, G., Collins, F. S., Chen, Y.-D. I., Caulfield, M. J., Campbell, H., Burtt, N. P., Bonnycastle, L. L., Boomsma, D. I., Boekholdt, S. M., Bergman, R. N., Barroso, I., Bandinelli, S., Ballantyne, C. M., Assimes, T. L., Quertermous, T., Altshuler, D., Seielstad, M., Wong, T. Y., Tai, E. S., Feranil, A. B., Kuzawa, C. W., Adair, L. S., Taylor, H. A., Jr., Borecki, I. B., Gabriel, S. B., Wilson, J. G., Holm, H., Thorsteinsdottir, U., Gudnason, V., Krauss, R. M., Mohlke, K. L., Ordovas, J. M., Munroe, P. B., Kooner, J. S., Tall, A. R., Hegele, R. A., Kastelein, J. J. P., Schadt, E. E., Rotter, J. I., Boerwinkle, E., Strachan, D. P., Mooser, V., Stefansson, K., Reilly, M. P., Samani, N. J., Schunkert, H., Cupples, L. A., Sandhu, M. S., Ridker, P. M., Rader, D. J., van Duijn, C. M., Peltonen, L., Abecasis, G. R., Boehnke, M., & Kathiresan, S. (2010). Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 466(7307), 707–713.PubMedCrossRef Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., Johansen, C. T., Fouchier, S. W., Isaacs, A., Peloso, G. M., Barbalic, M., Ricketts, S. L., Bis, J. C., Aulchenko, Y. S., Thorleifsson, G., Feitosa, M. F., Chambers, J., Orho-Melander, M., Melander, O., Johnson, T., Li, X., Guo, X., Li, M., Shin Cho, Y., Jin Go, M., Jin Kim, Y., Lee, J.-Y., Park, T., Kim, K., Sim, X., Twee-Hee Ong, R., Croteau-Chonka, D. C., Lange, L. A., Smith, J. D., Song, K., Hua Zhao, J., Yuan, X., Luan, J. A., Lamina, C., Ziegler, A., Zhang, W., Zee, R. Y. L., Wright, A. F., Witteman, J. C. M., Wilson, J. F., Willemsen, G., Wichmann, H. E., Whitfield, J. B., Waterworth, D. M., Wareham, N. J., Waeber, G., Vollenweider, P., Voight, B. F., Vitart, V., Uitterlinden, A. G., Uda, M., Tuomilehto, J., Thompson, J. R., Tanaka, T., Surakka, I., Stringham, H. M., Spector, T. D., Soranzo, N., Smit, J. H., Sinisalo, J., Silander, K., Sijbrands, E. J. G., Scuteri, A., Scott, J., Schlessinger, D., Sanna, S., Salomaa, V., Saharinen, J., Sabatti, C., Ruokonen, A., Rudan, I., Rose, L. M., Roberts, R., Rieder, M., Psaty, B. M., Pramstaller, P. P., Pichler, I., Perola, M., Penninx, B. W. J. H., Pedersen, N. L., Pattaro, C., Parker, A. N., Pare, G., Oostra, B. A., O’Donnell, C. J., Nieminen, M. S., Nickerson, D. A., Montgomery, G. W., Meitinger, T., McPherson, R., McCarthy, M. I., McArdle, W., Masson, D., Martin, N. G., Marroni, F., Mangino, M., Magnusson, P. K. E., Lucas, G., Luben, R., Loos, R. J. F., Lokki, M.-L., Lettre, G., Langenberg, C., Launer, L. J., Lakatta, E. G., Laaksonen, R., Kyvik, K. O., Kronenberg, F., Konig, I. R., Khaw, K.-T., Kaprio, J., Kaplan, L. M., Johansson, A., Jarvelin, M.-R., Cecile, J. W., Janssens, A., Ingelsson, E., Igl, W., Kees Hovingh, G., Hottenga, J.-J., Hofman, A., Hicks, A. A., Hengstenberg, C., Heid, I. M., Hayward, C., Havulinna, A. S., Hastie, N. D., Harris, T. B., Haritunians, T., Hall, A. S., Gyllensten, U., Guiducci, C., Groop, L. C., Gonzalez, E., Gieger, C., Freimer, N. B., Ferrucci, L., Erdmann, J., Elliott, P., Ejebe, K. G., Doring, A., Dominiczak, A. F., Demissie, S., Deloukas, P., de Geus, E. J. C., de Faire, U., Crawford, G., Collins, F. S., Chen, Y.-D. I., Caulfield, M. J., Campbell, H., Burtt, N. P., Bonnycastle, L. L., Boomsma, D. I., Boekholdt, S. M., Bergman, R. N., Barroso, I., Bandinelli, S., Ballantyne, C. M., Assimes, T. L., Quertermous, T., Altshuler, D., Seielstad, M., Wong, T. Y., Tai, E. S., Feranil, A. B., Kuzawa, C. W., Adair, L. S., Taylor, H. A., Jr., Borecki, I. B., Gabriel, S. B., Wilson, J. G., Holm, H., Thorsteinsdottir, U., Gudnason, V., Krauss, R. M., Mohlke, K. L., Ordovas, J. M., Munroe, P. B., Kooner, J. S., Tall, A. R., Hegele, R. A., Kastelein, J. J. P., Schadt, E. E., Rotter, J. I., Boerwinkle, E., Strachan, D. P., Mooser, V., Stefansson, K., Reilly, M. P., Samani, N. J., Schunkert, H., Cupples, L. A., Sandhu, M. S., Ridker, P. M., Rader, D. J., van Duijn, C. M., Peltonen, L., Abecasis, G. R., Boehnke, M., & Kathiresan, S. (2010). Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 466(7307), 707–713.PubMedCrossRef

172.

Köttgen, A., Pattaro, C., Boger, C. A., Fuchsberger, C., Olden, M., Glazer, N. L., Parsa, A., Gao, X., Yang, Q., Smith, A. V., O’Connell, J. R., Li, M., Schmidt, H., Tanaka, T., Isaacs, A., Ketkar, S., Hwang, S.-J., Johnson, A. D., Dehghan, A., Teumer, A., Pare, G., Atkinson, E. J., Zeller, T., Lohman, K., Cornelis, M. C., Probst-Hensch, N. M., Kronenberg, F., Tonjes, A., Hayward, C., Aspelund, T., Eiriksdottir, G., Launer, L. J., Harris, T. B., Rampersaud, E., Mitchell, B. D., Arking, D. E., Boerwinkle, E., Struchalin, M., Cavalieri, M., Singleton, A., Giallauria, F., Metter, J., de Boer, I. H., Haritunians, T., Lumley, T., Siscovick, D., Psaty, B. M., Zillikens, M. C., Oostra, B. A., Feitosa, M., Province, M., de Andrade, M., Turner, S. T., Schillert, A., Ziegler, A., Wild, P. S., Schnabel, R. B., Wilde, S., Munzel, T. F., Leak, T. S., Illig, T., Klopp, N., Meisinger, C., Wichmann, H. E., Koenig, W., Zgaga, L., Zemunik, T., Kolcic, I., Minelli, C., Hu, F. B., Johansson, A., Igl, W., Zaboli, G., Wild, S. H., Wright, A. F., Campbell, H., Ellinghaus, D., Schreiber, S., Aulchenko, Y. S., Felix, J. F., Rivadeneira, F., Uitterlinden, A. G., Hofman, A., Imboden, M., Nitsch, D., Brandstatter, A., Kollerits, B., Kedenko, L., Magi, R., Stumvoll, M., Kovacs, P., Boban, M., Campbell, S., Endlich, K., Volzke, H., Kroemer, H. K., Nauck, M., Volker, U., Polasek, O., Vitart, V., Badola, S., Parker, A. N., Ridker, P. M., Kardia, S. L. R., Blankenberg, S., Liu, Y., Curhan, G. C., Franke, A., Rochat, T., Paulweber, B., Prokopenko, I., Wang, W., Gudnason, V., Shuldiner, A. R., Coresh, J., Schmidt, R., Ferrucci, L., Shlipak, M. G., van Duijn, C. M., Borecki, I., Kramer, B. K., Rudan, I., Gyllensten, U., Wilson, J. F., Witteman, J. C., Pramstaller, P. P., Rettig, R., Hastie, N., Chasman, D. I., Kao, W. H., Heid, I. M., & Fox, C. S. (2010). New loci associated with kidney function and chronic kidney disease. Nat Genet, 42(5), 376–384.PubMedCrossRef

173.

Kettunen, J., Tukiainen, T., Sarin, A.-P., Ortega-Alonso, A., Tikkanen, E., Lyytikainen, L.-P., Kangas, A. J., Soininen, P., Wurtz, P., Silander, K., Dick, D. M., Rose, R. J., Savolainen, M. J., Viikari, J., Kahonen, M., Lehtimaki, T., Pietilainen, K. H., Inouye, M., McCarthy, M. I., Jula, A., Eriksson, J., Raitakari, O. T., Salomaa, V., Kaprio, J., Jarvelin, M.-R., Peltonen, L., Perola, M., Freimer, N. B., Ala-Korpela, M., Palotie, A., & Ripatti, S. (2012). Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet, 44(3), 269–276.PubMedCrossRef

174.

Suhre, K., Shin, S.-Y., Petersen, A.-K., Mohney, R. P., Meredith, D., Wagele, B., et al. (2011). Human metabolic individuality in biomedical and pharmaceutical research. Nature, 477(7362), 54–60.PubMedCrossRef

175.

Nicholson, G., Rantalainen, M., Li, J. V., Maher, A. D., Malmodin, D., Ahmadi, K. R., Faber, J. H., Barrett, A., Min, J. L., Rayner, N. W., Toft, H., Krestyaninova, M., Viksna, J., Neogi, S. G., Dumas, M.-E., Sarkans, U., Donnelly, P., Illig, T., Adamski, J., Suhre, K., Allen, M., Zondervan, K. T., Spector, T. D., Nicholson, J. K., Lindon, J. C., Baunsgaard, D., Holmes, E., McCarthy, M. I., Holmes, C. C., & The Mol, P. C. (2011). A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet, 7(9), e1002270.PubMedCrossRef

176.

Barabasi, A.-L., & Oltvai, Z. N. (2004). Network biology: understanding the cell’s functional organization. Nat Rev Genet, 5(2), 101–113.PubMedCrossRef

177.

Barabasi, A.-L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: a network-based approach to human disease. Nat Rev Genet, 12(1), 56–68.PubMedCrossRef

178.

Emmert-Streib, F., & Glazko, G. V. (2011). Network biology: a direct approach to study biological function. Wiley Interdiscip Rev Syst Biol Med, 3(4), 379–391.PubMedCrossRef

179.

Keller, B. J., Martini, S., Sedor, J. R., & Kretzler, M. (2012). A systems view of genetics in chronic kidney disease. Kidney Int, 81(1), 14–21.PubMedCrossRef

180.

He, J. C., Chuang, P. Y., Ma’Ayan, A., & Iyengar, R. (2012). Systems biology of kidney diseases. Kidney Int, 81(1), 22–39.PubMedCrossRef

181.

Schadt, E., Zhang, B., & Zhu, J. (2009). Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatments. Gen, 136(2), 259–269.

182.

Ostrowski, J., & Wyrwicz, L. S. (2009). Integrating genomics, proteomics and bioinformatics in translational studies of molecular medicine. Expert Rev Mol Diagn, 9(6), 623–630.PubMedCrossRef

183.

Ideker, T., & Krogan, N. J. (2012). Differential network biology. Mol Syst Biol, 8, 565.PubMedCrossRef

184.

Schadt, E. E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum, P. Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C., Zhu, J., Millstein, J., Sieberts, S., Lamb, J., GuhaThakurta, D., Derry, J., Storey, J. D., Avila-Campillo, I., Kruger, M. J., Johnson, J. M., Rohl, C. A., van Nas, A., Mehrabian, M., Drake, T. A., Lusis, A. J., Smith, R. C., Guengerich, F. P., Strom, S. C., Schuetz, E., Rushmore, T. H., & Ulrich, R. (2008). Mapping the genetic architecture of gene expression in human liver. PLoS Biol, 6(5), e107.PubMedCrossRef

185.

Mirel, B., Eichinger, F., Keller, B. J., & Kretzler, M. (2011). A cognitive task analysis of a visual analytic workflow: exploring molecular interaction networks in systems biology. J Biomed Discov Collab, 6, 1–33.PubMedCrossRef

186.

Bergholdt, R., Brorsson, C., Palleja, A., Berchtold, L. A., Fløyel, T., Bang-Berthelsen, C. H., Frederiksen, K. S., Jensen, L. J., Størling, J., & Pociot, F. (2012). Identification of novel type 1 diabetes candidate genes by integrating genome-wide association data, protein-protein interactions, and human pancreatic islet gene expression. Diabetes, 61(4), 954–962.PubMedCrossRef

187.

Friend, S. H., & Ideker, T. (2011). POINT: are we prepared for the future doctor visit? Nat Biotech, 29(3), 215–218.CrossRef

188.

Kohane, I. S., & Margulies, D. M. (2011). COUNTERPOINT: do not opine before it’s time. Nat Biotech, 29(3), 218–219.CrossRef

189.

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 13(11), 2498–2504.PubMedCrossRef

190.

Bhavnani, S., Ganesan, A., Hall, T., Maslowski, E., Eichinger, F., Martini, S., Saxman, P., Bellala, G., & Kretzler, M. (2010). Discovering hidden relationships between renal diseases and regulated genes through 3D network visualizations. BMC Res Notes, 3(1), 296.PubMedCrossRef

191.

Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., Cheng, Y., Clark, M. J., Im, H., Habegger, L., Balasubramanian, S., O’Huallachain, M., Dudley, J. T., Hillenmeyer, S., Haraksingh, R., Sharon, D., Euskirchen, G., Lacroute, P., Bettinger, K., Boyle, A. P., Kasowski, M., Grubert, F., Seki, S., Garcia, M., Whirl-Carrillo, M., Gallardo, M., Blasco, M. A., Greenberg, P. L., Snyder, P., Klein, T. E., Altman, R. B., Butte, A. J., Ashley, E. A., Gerstein, M., Nadeau, K. C., Tang, H., & Snyder, M. (2012). Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell, 148(6), 1293–1307.PubMedCrossRef

192.

Atkinson, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., Hoth, D. F., Oates, J. A., Peck, C. C., Schooley, R. T., Spilker, B. A., Woodcock, J., Zeger, S. L., & Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 69(3), 89–95.CrossRef

193.

Mischak, H., Allmaier, G., Apweiler, R., Attwood, T., Baumann, M., Benigni, A., et al. (2010). Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med, 2(46), 46ps42.PubMedCrossRef

194.

Matheis, K., Laurie, D., Andriamandroso, C., Arber, N., Badimon, L., Benain, X., Bendjama, K., Clavier, I., Colman, P., Firat, H., Goepfert, J., Hall, S., Joos, T., Kraus, S., Kretschmer, A., Merz, M., Padro, T., Planatscher, H., Rossi, A., Schneiderhan-Marra, N., Schuppe-Koistinen, I., Thomann, P., Vidal, J.-M., & Molac, B. (2011). A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today, 16(13–14), 600–608.PubMedCrossRef

195.

Hill, A. B. (1965). The environment and disease: association or causation? Proc R Soc Med, 58(5), 295–300.PubMed

196.

Slocum, J. L., Heung, M., & Pennathur, S. (2012). Marking renal injury: can we move beyond serum creatinine? Transl Res, 159(4), 277–289.PubMedCrossRef

197.

Ju, W., Smith, S., & Kretzler, M. (2012). Genomic biomarkers for chronic kidney disease. Transl Res, 159(4), 290–302.PubMedCrossRef

198.

Sotiriou, C., & Piccart, M. J. (2007). Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer, 7(7), 545–553.PubMedCrossRef

199.

Dabbs, D. J., Klein, M. E., Mohsin, S. K., Tubbs, R. R., Shuai, Y., & Bhargava, R. (2011). High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the oncotype DX test: an independent quality assurance study. J Clin Oncol, 29(32), 4279–4285.PubMedCrossRef

200.

Ignatiadis, M., & Sotiriou, C. (2012). Breast cancer: should we assess HER2 status by Oncotype DX®? Nat Rev Clin Oncol, 9(1), 12–14.CrossRef

201.

Coombes, K. R., Wang, J., & Baggerly, K. A. (2007). Microarrays: retracing steps. Nat Med, 13(11), 1276–1277.PubMedCrossRef

202.

Baggerly, K. A., & Coombes, K. R. (2009). Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat, 3(4), 1309–1334.CrossRef

203.

No authors listed (2010). Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 28(35):5229–5229

204.

Potti, A., Mukherjee, S., Petersen, R., Dressman, H. K., Bild, A., Koontz, J., et al. (2011). Retraction: a genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570–80. New Engl J Med, 364(12), 1176–1176.PubMedCrossRef

205.

Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., Harpole, D., Marks, J., Berchuck, A., Ginsburg, G. S., Febbo, P., Lancaster, J., & Nevins, J. R. (2011). Retraction: genomic signatures to guide the use of chemotherapeutics. Nat Med, 17(1), 135–135.PubMedCrossRef

206.

Hayden, E.C. (2012) Lapses in oversight compromise omics results. US board calls for tighter control of test-based data. Nature [23 March 2012].

207.

Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O.M., Dunning, M.J., et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (in press) (Published online, April 18, 2012).

208.

Monnier, V. M., Vishwanath, V., Frank, K. E., Elmets, C. A., Dauchot, P., & Kohn, R. R. (1986). Relation between complications of type i diabetes mellitus and collagen-linked fluorescence. New Engl J Med, 314(7), 403–408.PubMedCrossRef

209.

Sun, J. K., Keenan, H. A., Cavallerano, J. D., Asztalos, B. F., Schaefer, E. J., Sell, D. R., Strauch, C. M., Monnier, V. M., Doria, A., Aiello, L. P., & King, G. L. (2011). Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration. The Joslin 50-Year Medalist Study. Diabetes Care, 34(4), 968–974.PubMedCrossRef

210.

Mirel, B., Eichinger, F., Nair, V., & Kretzler, M. (2009). Integrating automated workflows, human intelligence and collaboration. Summit on Translat Bioinforma, 2009, 79–83.PubMed

211.

Derry, J. M. J., Mangravite, L. M., Suver, C., Furia, M. D., Henderson, D., Schildwachter, X., Bot, B., Izant, J., Sieberts, S. K., Kellen, M. R., & Friend, S. H. (2012). Developing predictive molecular maps of human disease through community-based modeling. Nat Genet, 44(2), 127–130.PubMedCrossRef

Titel: Perspectives on Systems Biology Applications in Diabetic Kidney Disease
verfasst von: Claudiu V. Komorowsky
Frank C. Brosius 3rd
Subramaniam Pennathur
Matthias Kretzler
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 4/2012
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-012-9382-7

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Erratum to: Cardiovascular Disease Risk in Young People with Type 1 Diabetes

The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence

The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis

What Do We Know and We Do Not Know About Cardiovascular Autonomic Neuropathy in Diabetes